Partnerships and Licensing

Exicure is using its proprietary SNA technology platform to build a broad pipeline of products for a range of diseases with unmet medical need.  The company's strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform through in-house development, collaborations and licensing.

Exicure may also establish platform partnerships with pharmaceutical companies across multiple indications or within specific therapeutic areas.

For more information regarding Exicure's partnering strategy, please contact Gordon Beck, Ph.D., VP Business Development, gbeck at

Latest News

  • AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform

    April 22, 2015go

  • C&EN News Explores Immune Modulating Capabilities of SNA Technology

    April 13, 2015go

  • Biotuesdays: In Conversation with David Giljohann

    February 10, 2015go

  • AuraSense Therapeutics Adds to Series C Financing

    February 4, 2015go

  • David Giljohann Named Among Top 40 Under 40 by Analytical Scientist

    October 29, 2014go